CTLA4 and type 1 diabetes mellitus: All our patients were receiving anti-PD1/PD-L1 monoclonal antibodies, either as monotherapy or in combination with different agents, and we observed that combination with anti-CTLA4 antibodies may accelerate the onset of ICI-induced IDDM.